Researchers assess whether differences in control group outcomes across antidepressant trials reflect methodological variability, patient expectations, or limitations in blinding effectiveness.
A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing 45 kg or more, expanding its use beyond adults.
Not all screen time is created equal. That’s the message from a recent editorial, which challenges the idea that all forms of problematic internet use led to the same cognitive consequences.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A new meta-analysis of 11 randomized controlled trials found that patients began regaining weight as early as 8 weeks after discontinuing anti-obesity medications, with weight gain continuing through 52 weeks.